Trinity Biotech acquires RDI

Trinity Biotech plc today announced that it has completed the acquisition of Research Diagnostics Inc of Flanders, New Jersey.

Trinity Biotech has acquired the business of RDI for $4.2m (€3.2m). RDI provides a comprehensive range of immunodiagnostic products to research facilities, pharmaceutical companies, reference laboratories, diagnostic manufacturers, and universities worldwide.

The company’s revenue and profit performance has shown consistent growth with sales last year.

Ronan O’Caoimh, Trinity Biotech CEO, commented: “We are delighted to be deploying our cash resources to this earnings accretive acquisition. RDI is a natural fit with our existing operations in Fitzgerald in that it is particularly strong in supplying product to research facilities worldwide whereas Fitzgerald’s focus is on diagnostic manufacturers.

"There is minimal overlap in the products supplied by both companies. We are confident that the combination of both RDI and Fitzgerald will strengthen Trinity’s position in this segment of the life sciences market with combined turnover in excess of US$11 million.”